Sutro Biopharma is a smaller ADC (antibody ... The impact of AbbVie's Elahere is misrepresented in my eyes, as NCCN guidelines recommend its use with Avastin in low and medium FRa expressors ...

ImmunoGen’s lead development programme was a folate receptor alpha (FRa)-targeted ADC, which ultimately became Elahere (mirvetuximab soravtansine). Elahere suffered multiple development setbacks ...

Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug conjugate (ADC ...

CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere ... with the antibody drug conjugate (ADC), Filippos Vingopoulos, MD, an ...

The grants, which FRA and its parent U.S. Dept. of Transportation announced on Oct. 30, will go to projects in 41 states and the District of Columbia. The projects span a range of types of work ...

The biotech chose to add a second candidate in April when it inked a $1.8 billion deal to buy ProfoundBio for a rival to AbbVie’s Elahere. It had a third asset thrust into its hands in August ...

Mirvetuximab soravtansine demonstrated efficacy in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, achieving a 51.9% objective response rate in the PICCOLO trial.

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

Additionally, Ms. White helped to maximize the successful commercial launch of ELAHERE®, a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. Before joining ...

Global Elahere net revenues were $139 million ... AbbVie showcased new data from its innovative antibody-drug conjugate (ADC) platform in tumor types with high unmet needs. Highlights included ...

We are also seeing nice sequential revenue growth from Elahere and Epkinly ... Once approved, Teliso-V will become the first c-Met targeted ADC to enter non-small cell lung cancer, a segment ...